| Autor: |
Johnson, Isla M., Karrar, Omer, Rana, Masooma, Iftikhar, Moazah, Chen, Sunny, McCullough, Kristen, Saliba, Antoine N., Al‐Kali, Aref, Alkhateeb, Hassan, Begna, Kebede, Litzow, Mark, Hogan, William J., Shah, Mithun, Patnaik, Mrinal M., Pardanani, Animesh, Hermann, Joerg, Tefferi, Ayalew, Gangat, Naseema |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Apr2024, Vol. 204 Issue 4, p1232-1237, 6p |
| Abstrakt: |
Summary: Among 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non‐ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four patients had more than one cardiac complication. Baseline characteristics included median age ± interquartile range; 73 ± 5 years; 87% males; 96% with cardiovascular risk factors; and 90% with preserved baseline ejection fraction. In multivariate analysis, males were more likely (p = 0.02) and DNMT3A‐mutated cases less likely (p < 0.01) to be affected. Treatment‐emergent cardiac events were associated with a trend towards lower composite remission rates (43% vs. 62%; p = 0.09) and shorter survival (median 7.7 vs. 13.2 months; p < 0.01). These observations were retrospectively retrieved and warrant further prospective examination. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text